United States· US:0002-7678_8f4af9a3-1e45-4174-a2a7-31477f46901a
CYRAMZA
A medicinal product containing ramucirumab, registered in United States by Eli Lilly and Company.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ramucirumab
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 12, 2026
Packs & prices · 1
- ndc1100027678011 VIAL, SINGLE-DOSE in 1 CARTON (0002-7678-01) / 50 mL in 1 VIAL, SINGLE-DOSE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ramucirumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONEli Lilly Nederland B.V.
- United KingdomCyramza 100mg/10ml concentrate for solution for infusion vialsOriginalis B.V.
- CzechiaCYRAMZAEli Lilly Nederland B.V., Utrecht
- BelgiumCyramza 10 mg/mlEli Lilly Nederland
- SwitzerlandCyramza
- FinlandCyramzaEli Lilly Nederland B.V
- Japanラムシルマブ（遺伝子組換え）日本イーライリリー
- IrelandCyramza 10 mg/ml Concentrate for solution for infusionEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cyramza
- Liechtenstein · Cyramza
- Norway · Cyramza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2ce818ea-eb3c-4288-a05a-b6caf7aae031 GET /v1/drugs/2ce818ea-eb3c-4288-a05a-b6caf7aae031?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"livertox": {
"summary": null,
"livertox_id": null,
"hepatotoxicity_score": 5
},
"productid": "0002-7678_8f4af9a3-1e45-4174-a2a7-31477f46901a",
"productndc": "0002-7678",
"dosage_form": "SOLUTION",
"dea_schedule": null,
"product_type": "HUMAN PRESCRIPTION DRUG",
"substance_name": "RAMUCIRUMAB",
"proprietary_name": "CYRAMZA",
"active_ingred_unit": "mg/mL",
"application_number": "BLA125477",
"marketing_category": "BLA",
"nonproprietary_name": "ramucirumab",
"start_marketing_date": "20140421",
"active_numerator_strength": "10"
}See everything about ramucirumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.